Additional dosing, storing, and handling information

for CLEVIPREX® (clevidipine)

Cleviprex vials with temperature and light icons

No experience of overdosage in human clinical trials1

  • The expected major effects of overdose would be hypotension and reflex tachycardia

In case of suspected overdosage, CLEVIPREX should be discontinued immediately and the patient’s blood pressure should be supported.

  • Discontinuation of CLEVIPREX leads to a reduction in antihypertensive effects within 5 to 15 minutes

CLEVIPREX single-use, ready-to-use vials

Maximum dose1

  • Most patients treated with maximum doses of 16 mg/hr (32 mL/hr) or less
  • There is limited short-term experience with doses as high as 32 mg/hr (64 mL/hr)
  • Because of lipid load restrictions, no more than 1,000 mL or an average of 21 mg/hr (42 mL/hr) of CLEVIPREX infusion is recommended per 24-hour period
  • There is little experience with infusion durations beyond 72 hours at any dose

CLEVIPREX is Y-site compatible with several IV bag fluids1

Y-site IV fluid bag

Considerations when using a Y-site to administer CLEVIPREX

  • Do not dilute CLEVIPREX
  • Do not administer CLEVIPREX in the same line as other medications

Compatible IV bag fluids include:

  • Water for Injection, USP
  • 0.9% Sodium Chloride Injection, USP
  • 5% Dextrose Injection, USP
  • 5% Dextrose in 0.9% Sodium Chloride Injection, USP
  • 5% Dextrose in Lactated Ringer’s Injection, USP
  • Lactated Ringer’s Injection, USP
  • 10% Amino Acid

Available resources

Keep CLEVIPREX information readily available with our point-of-care resources. Contact a Chiesi sales representative to order.

Storage and handling considerations for CLEVIPREX1


Light Icon

Light sensitivity

CLEVIPREX is photosensitive; leave vials in cartons until use

  • Protection from light during administration is not required

Temperature Icon

Temperature guidelines

  • Store vials in cartons refrigerated at 2–8 °C (36–46 °F); do not freeze
  • Vials in cartons may be transferred to storage at 25 °C (77 °F, USP controlled room temperature) for up to 2 months
    • Upon transfer to room temperature, mark vials in cartons “This product was removed from the refrigerator on __/__/__ date. It must be used or discarded 2 months after this date or the labeled expiration date (whichever date comes first)”
  • Do not return CLEVIPREX to refrigerated storage after switching to USP controlled room temperature
  • Once stopper is punctured, use within 12 hours and discard any unused portion

Individualized, titratable administration1

CLEVIPREX offers low-volume, non–weight-based dosing that is independent of renal or hepatic function.

50 mL and 100 mL CLEVIPREX single-use, ready-to-use vials

The CLEVIPREX Dosing and Administration Guide

Use this guide as a quick reference to help with CLEVIPREX dosing and administration.


Order a supply of CLEVIPREX

Find wholesaler numbers and supply information for CLEVIPREX.